Localized Osteosarcoma in Upper Egypt: A Clinical Prediction Model
Localized Osteosarcoma of Extremities: Developing a Clinical Prediction Model From a Country With Limited Resources
1 other identifier
observational
30
1 country
1
Brief Summary
To assess survival outcome of pediatric patients with localized osteosarcoma of the extremities in Upper Egypt, identify factors of prognostic significance for survival, and to determine factors predictive of surgical methods employed in these patients, and developing a clinical model for risk prediction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2018
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 20, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
August 25, 2018
CompletedFirst Submitted
Initial submission to the registry
February 9, 2019
CompletedFirst Posted
Study publicly available on registry
February 15, 2019
CompletedFebruary 15, 2019
February 1, 2019
7 months
February 9, 2019
February 11, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Overall survival (OS)
Participants will be retrospectively followed forward in time from the date of initiation of treatment till death from any cause, an expected average of 5 years
From date of treatment initiation until the date of death from any cause or patients censored at last follow up, whichever came first, assessed up to 60 months
Metastasis-Free survival (MFS)
Participants will be retrospectively followed forward in time from the date of initiation of treatment till the occurrence of systemic recurrence, an expected average of 5 years
From date of treatment initiation until the date of first documented systemic recurrence or patients censored at last follow up, whichever came first, assessed up to 60 months
Eligibility Criteria
30 pediatric patients with a histologically-verified non-metastatic osteosarcoma of the extremities treated at South Egypt Cancer Institute with a unified chemotherapy protocol between January 2001 and December 2015.
You may qualify if:
- Patients whose age less than 19 years.
- Patients diagnosed with verified osteosarcoma involving the extremities.
You may not qualify if:
- Patients whose age more than 19 years.
- Non-extremities Osteosarcoma .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assiut University
Asyut, 71515, Egypt
Related Publications (1)
Morsy AM, Abdelgawad MI, Ahmed BM, Rezk KM, Aboelgheit AM, Ramadan IK, Kamel HEM, Fouad DM, Herdan RA, Shabaan SH, Eltyb HA. Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt. J Pediatr Hematol Oncol. 2019 Aug;41(6):e371-e383. doi: 10.1097/MPH.0000000000001407.
PMID: 30629005BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Lecturer, Pediatric Oncology Department
Study Record Dates
First Submitted
February 9, 2019
First Posted
February 15, 2019
Study Start
January 1, 2018
Primary Completion
July 20, 2018
Study Completion
August 25, 2018
Last Updated
February 15, 2019
Record last verified: 2019-02